Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2).
Journal Information
Full Title: J Hematol Oncol
Abbreviation: J Hematol Oncol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declarations Ethics approval and consent to participateThis study was performed in accordance with the Declaration of Helsinki and was approved by the institutional independent ethics committee. Consent for publicationNot applicable. Competing interestsX-HF is employed by Legend Biotech. All other authors declare that they have no competing interests. Competing interests X-HF is employed by Legend Biotech. All other authors declare that they have no competing interests."
"Funding The study was funded by Key Research and Development Plan of ShaanXi Province, Project 2018SF-002 awarded to W–H Zhao, Project 2017ZDXM-SF-25–6 (Approval No. 2018ZDXM-SF-039) awarded to A-L He; National Natural Science Foundation of China (No. 81970189) awarded to J Xu. Nanjing Legend Biotech Co. was involved in the design of the study and collection, analysis, and interpretation of data. Editorial support for the manuscript was funded by Janssen Global Services."
"Trial registration Clinicaltrials.gov NCT03090659 (retrospectively registered on March 27, 2017); ChiCTR-ONH-17012285."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025